Skip to main content
SpringerLink
Log in

Biobanking for Rare Diseases – Impact on Personalised Medicine

  • Chapter
  • First Online:
Rare Diseases

Part of the book series: Advances in Predictive, Preventive and Personalised Medicine ((APPPM,volume 6))

  • 1118 Accesses

Abstract

For the past 15 years biobanks have been infrastructures that have permitted to ensure the quality of the biological resources used as well as guarantee the rights of stakeholders. Due to their medical and scientific expertise, they offer collections of human biological resources that meet with research project requirements. Because of their secure storage capacities, biobanks are front-line actors in collection management by enabling their development, ensuring their continued existence and their valorisation in relevant research projects. At the cross-roads of patient inclusion, sample and associated data collection and logistical facilities, biobanks have become a significant partner of translational research and personalised medicine, almost essential in the field of rare diseases research as a result of the difficulty of obtaining the samples.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Oktay MH, Hui P (2012) Molecular pathology as the driving force for personalized oncology. Expert Rev Mol Diagn 12(8):811–813

    Article  CAS  PubMed  Google Scholar 

  2. Kalia M (2013) Personalized oncology: recent advances and future challenges. Metabolism 62:S11–S14, Suppl1

    Article  CAS  PubMed  Google Scholar 

  3. Palau F (2012) Personalized medicine in rare disease. Personalized Med 9(2):137–141

    Article  Google Scholar 

  4. Rugnetta M, Whitney K (2009) Paving the way for personalized medicine. Sci Prog. http://www.scienceprogress.org/wp-content/uploads/2009/09/personalized_medicine.pdf. Accessed 12 Dec 2012

  5. Lehrach H (2012) A revolution in healthcare: challenges and opportunities for personalized medicine. Personalized Med 9(2):105–108

    Article  Google Scholar 

  6. Clotworthy M (2012) The application of human tissue for drug discovery and development. Expert Opin Drug Discov 7(7):543–547

    Article  CAS  PubMed  Google Scholar 

  7. Yüzbaşioğlu A, Ozgüç M (2012) Biobanking: sample acquisition and quality assurance for ‘omics’ research. N Biotechnol 30(3):339–342

    PubMed  Google Scholar 

  8. OECD (2000) Biological resources centres: underpinning the future of life sciences and biotechnology. DSTI/STP/BIO 4 REV1 http://www.oecd.org/sti/biotech/2487422.pdf. Accessed 30 Dec 2012

  9. European Strategy Forum in Research Infrastructures (ESFRI) (2012) European research infrastructures with global impact. http://www.copori.eu/_media/ESFRI_Brochure_210912_lowres.pdf. Accessed 30 Dec 2012

  10. Meeting Europe’s challenges: the role and importance of biological and medical sciences research infrastructures (2010) http://www.eurobioimaging.eu/sites/default/files/BMS%20Strategy%20Paper.pdf. Accessed 30 Dec 2012

  11. Meijer I, Mattson P, Nooijen A, Boekholt P, Molas Gallart J, Amat CB (2010) BBMRI: an evaluation strategy for socio-economic impact assessment http://www.technopolis-group.com/resources/downloads/life_sciences/1093_BBMRIfinalreport_100921.pdf. Accessed 30 Dec 2012

  12. OECD best practice guidelines for biological resource centres (2007) http://www.oecd.org/sti/biotechnologypolicies/38777417.pdf. Accessed 30 Dec 2012

  13. Gottweis H, Kaye J, Bignami F, Rial-Sebbag E, Lattanzi R, Macek M (2012) Biobanks for Europe – a challenge for governance. doi:10.2777/68942. http://www.coe.int/t/dg3/healthbioethic/Activities/10_Biobanks/biobanks_for_Europe.pdf. Accessed 30 Dec 2012

  14. Martín Uranga A, Martín-Arribas MC, di Donato JH, de la Paz Posada M (2005) Outstanding legal and ethical issues on biobanks. Instituto de Salud Carlos III, Madrid

    Google Scholar 

  15. Norme NF S 96–900: Quality of Biological Resources Centres (BRC) – Quality management system of BRC and quality of biological resources. (2011) French document

    Google Scholar 

  16. Martín Uranga A, Martín-Arribas MC, di Donato JH, de la Paz Posada M (2005) Outstanding legal and ethical issues on biobanks. Instituto de Salud Carlos III, Madrid, Chapter 6

    Google Scholar 

  17. WIKI legal platform of BBMRI http://www.bbmri.eu/index.php?option=com_content&view=article&id=67&Itemid=58. Accessed 30 Dec 2012

  18. OECD best practice guidelines for biological resource centres (2007) Chapter best practice guidelines on human-derived material. http://www.oecd.org/sti/biotechnologypolicies/38777417.pdf. Accessed 30 Dec 2012

  19. Lochmüller H, Aymé S, Pampinella F, Melegh B, Kuhn K, Antonarakis SE, Meitinger T (2009) The role of biobanking in rare diseases: European Consensus Expert Group report. Biopreserv Biobank 7(3):155–156

    Article  PubMed  Google Scholar 

  20. Lochmüller H, Schneiderat P (2010) Biobanking in rare disorders. Adv Exp Med Biol 686:105–113

    Article  PubMed  Google Scholar 

  21. RD-CONNECT: an integrated platform connecting databases, registries, biobanks and clinical bioinformatics for rare disease research. http://www.rd-connect.eu/. Accessed 30 Dec 2012

  22. International Rare Disease Research Consortium. http://www.irdirc.org/. Accessed 30 Dec 2012

  23. Rare disorders research consortium of Oregon Health & science university. http://www.ohsu.edu/xd/research/clinical-research/hgi/consortium/. Accessed 30 Dec 2012

  24. Treat-NMD neuromuscular network. http://www.treat-nmd.eu/. Accessed 30 Dec 2012

  25. Moore HM, Kelly AB, Jewell SD, McShane LM, Clark DP, Greenspan R, Hayes DF, Hainaut P, Kim P, Mansfield EA, Potapova O, Riegman P, Rubinstein Y, Seijo E, Somiari S, Watson P, Weier HU, Zhu C, Vaught J (2011) Biospecimen reporting for improved study quality (BRISQ) Cancer Cytopathology. Cancer Cytopathol 119(2):92–102. doi 10.1002/cncy.20147

  26. Azimi-Nezhad M, Lambert D, Ottone C, Perrin C, Chapel C, Gaillard G, Pfister M, Masson C, Tabone E, Betsou F, Meyronet D, Ungeheuer MN, S-Siest V (2012) Influence of pre-analytical Variables on VEGF gene expression and circulating protein concentrations. Biopreserv Bioreposit 10(5):454–461

    Article  CAS  Google Scholar 

  27. González-Gross M, Breidenassel C, Gómez-Martínez S, Ferrari M, Béghin L, Spinneker A, Díaz LE, Maiani G, Demailly A, Al-Tahan J, Albers U, Wärnberg J, Stoffel-Wagner B, Jiménez-Pavón D, Libersa C, Pietrzik K, Marcos A, Stehle P (2008) Sampling and processing of fresh blood samples within a European multicenter nutritional study: evaluation of biomarker stability during transport and storage. Int J Obes (Lond) 32(Suppl 5):S66–S75

    Article  Google Scholar 

  28. Lehmann S, Roche S, Allory Y, Barthelaix A, Beaudeux JL, Berger F, Betsou F, Borg J, Dupuy A, Garin J, Quillard M, Lizard G, Peoc’h K, Riviere M, Ducoroy P (2009) Preanalytical guidelines for clinical proteomics investigation of biological fluids. Ann Biol Clin (Paris) 67(6):629–639, French

    CAS  Google Scholar 

  29. Stumm MM, Walker MR, Stork C, Hanoteau N, Wagner U, O’Reilly TM (2012) Validation of a postfixation tissue storage and transport medium to preserve histopathology and molecular pathology analyses (total and phosphoactivated proteins, and FISH). Am J Clin Pathol 137(3):429–436

    Article  PubMed  Google Scholar 

  30. Rai AJ, Vitzthum F (2006) Effects of preanalytical variables on peptide and protein measurements in human serum and plasma: implications for clinical proteomics. Expert Rev Proteomics 3:409–426

    Article  CAS  PubMed  Google Scholar 

  31. Policepatil SM, Caplan RH, Dolan M (2012) Hypocalcemic myopathy secondary to hypoparathyroidism. Wisc Med Soc 111(4):173–175

    Google Scholar 

  32. Amann G, Zehntner C, Marti F, Colucci G (2012) Effect of acceleration forces during transport through a pneumatic tube system on ROTEM® analysis. Clin Chem Lab Med 50(8):1335–1342

    Article  CAS  PubMed  Google Scholar 

  33. OECD best practice guidelines for biological resource centres (2007) Chapter II, p 16. http://www.oecd.org/sti/biotechnologypolicies/38777417.pdf. Accessed 30 Dec 2012

  34. Marko-Vaga G, Végvari A, Welinder C, Lindberg H, Rezeli M, Edula G, Svensson KJ, Belting M, Laurell T, Fehniger T (2012) Standardization and utilization of biobank resources in clinical protein science with examples of emerging applications. J Proteome Res 11(11):5124–5134

    Article  Google Scholar 

  35. Kugler KG, Hackl WO, Mueller L, Fiegl H, Graber A, Pfeiffer R (2011) The impact of sample storage time on estimates of association in biomarker discovery studies. J Clin Bioinform 1:9

    Article  Google Scholar 

  36. P3G http://p3g.org/. Accessed 30 Dec 2012

  37. I3-CRB http://www.i3crb.fr/. Accessed 30 Dec 2012

  38. EuroBioBank http://www.eurobiobank.org/. Accessed 30 Dec 2012

  39. TV GSO: Virtuel tumor bank of Canceropole GSO http://www.biobank-gso.org/apex/f?p=200:1:1682323211602182. Accessed 30 Dec 2012

  40. Clerkin P, Buckley BS, Murphy AW, MacFarlane AE (2012) Patients’ views about the use of their personal information from general practice medical records in health research: a qualitative study in Ireland. Fam Pract. doi:10.1093/fampra/cms036

    PubMed  Google Scholar 

  41. Kosseim P (2011) Banking for the future: “Informing” consent in the context of biobanks. Paper submitted at the OIV International Seminar on the UNSECO Universal Declaration on Bioethics and Human rights. http://www.priv.gc.ca/media/sp-d/2011/SP-d_20110121_pk_e.asp. Accessed 30 Dec 2012

  42. Ensuring Consent & Revocation – A collaborative IT research project being undertaken by UK industry & academia. http://www.encore-project.info/index.html. Accessed 30 Dec 2012

  43. Presidential Commission for the study of bioethical issues (2012) Privacy and progress in whole genome sequencing. http://bioethics.gov/cms/sites/default/files/PrivacyProgress508.pdf. Accessed 12 Dec 2012

  44. Soto C, Tarrant C, Pritchard-Jones K, Dixon-Woods M (2012) Consent to tissue banking for research: qualitative study and recommendations. Arch Dis Child 97:632–636

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 3C-R, Castelginest, France

    Jeanne-Hélène di Donato

Authors
  1. Jeanne-Hélène di Donato
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeanne-Hélène di Donato .

Editor information

Editors and Affiliations

  1. Faculty of Medicine, Medical Biology, Hacettepe University, Ankara, Turkey

    Meral Özgüç

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

di Donato, JH. (2015). Biobanking for Rare Diseases – Impact on Personalised Medicine. In: Özgüç, M. (eds) Rare Diseases. Advances in Predictive, Preventive and Personalised Medicine, vol 6. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-9214-1_2

Download citation

  • DOI: https://doi.org/10.1007/978-94-017-9214-1_2

  • Published:

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-017-9213-4

  • Online ISBN: 978-94-017-9214-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation